Horizon Pharma PLC | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
81
220
861
516
758
962
Total Accounts Receivable
16
74
210
306
367
465
Inventories
9
17
18
175
62
51
Other Current Assets
5
16
16
42
43
49
Total Current Assets
111
326
1,106
1,038
1,230
1,527
Net Property, Plant & Equipment
4
7
14
23
20
20
Intangible Assets
131
771
1,936
3,219
2,876
2,552
Other Assets
-
7
12
10
36
45
Total Assets
280
1,135
3,059
4,292
4,166
4,146
ST Debt & Current Portion LT Debt
-
48
4
8
11
Accounts Payable
10
21
17
52
35
Income Tax Payable
-
13
-
-
-
Other Current Liabilities
33
137
337
546
712
Total Current Liabilities
43
219
358
606
757
Long-Term Debt
220
297
1,133
1,800
1,891
Deferred Taxes
3
1
111
296
154
Other Liabilities
35
58
142
326
369
Total Liabilities
329
594
1,745
3,028
3,175
Common Equity (Total)
49
540
1,313
1,264
991
Total Shareholders' Equity
49
540
1,313
1,264
991
Total Equity
49
540
1,313
1,264
991
Liabilities & Shareholders' Equity
280
1,135
3,059
4,292
4,166

About Horizon Pharma

View Profile
Address
Connaught House
Dublin Dublin 4
Ireland
Employees -
Website http://www.horizontherapeutics.com
Updated 07/08/2019
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.